February 27, 2018

Monthly Publications Mixtape

Here is a selection of recent collaborative publications involving DF/HCC authors for your reading pleasure.

Network analysis of UBE3A/E6AP-associated proteins provides connections to several distinct cellular processes.
J Mol Biol. 2018 Feb 6.
Martínez-Noël G, Luck K, Kühnle S, Desbuleux A, Szajner P, Galligan JT, Rodriguez D, Zheng L, Boyland K, Leclere F, Zhong Q, Hill DE, Vidal M(DFCI) , Howley PM (HMS).
PMID: 29426014.

Integrative analysis of exogenous, endogenous, tumour and immune factors for precision medicine.
Gut. 2018 Feb 6.
Ogino S (DFCI), Nowak JA, Hamada T, Phipps AI, Peters U, Milner DA Jr, Giovannucci EL (HSPH), Nishihara R(DFCI), Giannakis M, Garrett WS (HSPH), Song M (MGH).
PMID: 29437869.

Durable clinical benefit in metastatic renal cell carcinoma patients who discontinue PD-1/PD-L1 therapy for immune-related adverse events (irAEs).
Cancer Immunol Res. 2018 Feb 1.
Martini DJ, Hamieh L, McKay RR, Harshman LC (DFCI), Brandao R, Norton CK, Steinharter JA, Krajewski KM (BWH), Gao X, Schutz FA, McGregor B (DFCI), Bosse D, Lalani AK, de Velasco G, Michaelson MD (MGH), McDermott DF (BIDMC), Choueiri TK (DFCI).   
PMID: 29437040.

Convergent therapeutic strategies to overcome the heterogeneity of acquired resistance in BRAFV600E colorectal cancer. 
Cancer Discov. 2018 Feb 5.
Hazar-Rethinam M, Kleyman M, Han GC, Liu D, Ahronian LG, Shahzade HA, Chen L, Parikh AR, Allen JN, Clark JW (MGH), Kwak EL, Faris JE, Murphy JE, Hong TS (MGH), Van Seventer EE, Nadres B, Hong CB, Gurski JM, Jessop NA, Dias-Santagata D, Iafrate AJ (MGH), Van Allen EM (DFCI), Corcoran RB (MGH). 
PMID: 29431697.

Insurance status and cancer treatment mediate the association between race/ethnicity and cervical cancer survival. 
PLoS One. 2018 Feb 15
Markt SC, Tang T, Cronin AM, Katz IT (BWH), Howitt BE, Horowitz NS (BWH), Lee LJ, Wright AA (DFCI). 
PMID: 29447263.

Targeting cytokine therapy to the pancreatic tumor microenvironment using PD-L1 specific VHHs. 
Cancer Immunol Res. 2018 Feb 19.
Dougan M, Ingram JR, Jeong HJ, Mosaheb MM, Bruck PT, Ali L, Pishesha N, Blomberg O, Tyler PM, Servos MM, Rashidian M, Nguyen QD, von Andrian UH(HMS), Ploegh HL,Dougan SK (DFCI). 
PMID: 29459478.

"I don't want to take chances.": A qualitative exploration of surgical decision making in young breast cancer survivors.
Psychooncology. 2018 Feb 24.
Rosenberg SM (DFCI), Greaney ML, Patenaude AF, Sepucha KR (MGH), Meyer ME, Partridge AH (DFCI).  
PMID: 29476578.

EWS/FLI Confers Tumor Cell Synthetic Lethality to CDK12 Inhibition in Ewing Sarcoma. 
Cancer Cell. 2018 Feb 12
Iniguez AB, Stolte B, Wang EJ, Conway AS, Alexe G, Dharia NV, Kwiatkowski N, Zhang T, Abraham BJ, Mora J, Kalev P, Leggett A, Chowdhury D (DFCI), Benes CH, Young RA, Gray NS (DFCI), Stegmaier K (DFCI). 
PMID: 29358035.

KRAS Dimerization Impacts MEK Inhibitor Sensitivity and Oncogenic Activity of Mutant KRAS.
Cell. 2018 Feb 8
Ambrogio C, Köhler J, Zhou ZW, Wang H (BIDMC), Paranal R, Li J, Capelletti M, Caffarra C, Li S, Lv Q, Gondi S, Hunter JC, Lu J, Chiarle R (BCH), Santamaría D, Westover KD, Jänne PA(DFCI).  
PMID: 29336889.